How I treat acute myeloid leukemia in the era of new drugs

The acute myeloid leukemia (AML) treatment landscape has changed substantially since 2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2, midostaurin and gilteritinib to target FLT3, and ivosidenib and enasidenib to target mutant isocitrate dehydrogenase 1 and 2,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2020-01, Vol.135 (2), p.85-96
Hauptverfasser:	DiNardo, Courtney D., Wei, Andrew H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aminopyridines - therapeutic use Aniline Compounds - therapeutic use Antineoplastic Agents - therapeutic use Biomarkers, Tumor - genetics Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Cytarabine - therapeutic use Daunorubicin - therapeutic use Female fms-Like Tyrosine Kinase 3 - antagonists & inhibitors fms-Like Tyrosine Kinase 3 - genetics Glycine - analogs & derivatives Glycine - therapeutic use Humans Isocitrate Dehydrogenase - antagonists & inhibitors Isocitrate Dehydrogenase - genetics Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - pathology Male Molecular Targeted Therapy Mutation Prognosis Pyrazines - therapeutic use Pyridines - therapeutic use Sialic Acid Binding Ig-like Lectin 3 - antagonists & inhibitors Sialic Acid Binding Ig-like Lectin 3 - genetics Staurosporine - analogs & derivatives Staurosporine - therapeutic use Sulfonamides - therapeutic use Triazines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!